Breaking the graft-versus-host-disease barrier: Mesenchymal stromal/stem cells as precision healers

References

• Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9(1):12. doi:10.1186/1478-811X-9-12.
   PubMedGoogle Scholar
• Ponnaiyan D, Bhat KM, Bhat GS. Comparison of immuno-phenotypes of stem cells from human dental pulp and periodontal ligament. Int J Immunopathol Pharmacol. 2012;25(1):127–134. doi:10.1177/039463201202500115.
   PubMed Web of Science ®Google Scholar
• Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195–202. doi:10.4252/wjsc.v6.i2.195.
   PubMedGoogle Scholar
• Caplan AI. Mesenchymal stem cells: time to change the name!. Stem Cells Transl Med. 2017;6(6):1445–1451. doi:10.1002/sctm.17-0051.
   PubMed Web of Science ®Google Scholar
• Blocki A, Wang Y, Koch M, et al. Not all MSCs can act as pericytes: functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev. 2013;22(17):2347–2355. doi:10.1089/scd.2012.0415.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi:10.1080/14653240600855905.
   PubMed Web of Science ®Google Scholar
• Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–848. doi:10.3727/096368915X689622.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu Y, Sun Y, et al. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res Ther. 2017;8(1):275. doi:10.1186/s13287-017-0716-x.
   PubMedGoogle Scholar
• Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019–1024. doi:10.1016/j.jcyt.2019.08.002.
   PubMed Web of Science ®Google Scholar
• Miclau K, Hambright WS, Huard J, Stoddart MJ, Bahney CS. Cellular expansion of MSCs: Shifting the regenerative potential. Aging Cell. 2023;22(1):e13759. doi:10.1111/acel.13759.
   PubMed Web of Science ®Google Scholar
• Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151–159. doi:10.1016/j.jcyt.2015.11.008.
   PubMed Web of Science ®Google Scholar
• Merimi M, El-Majzoub R, Lagneaux L, et al. The therapeutic potential of mesenchymal stromal cells for regenerative medicine: current knowledge and future understandings. Front Cell Dev Biol. 2021;9:661532. doi:10.3389/fcell.2021.661532.
   PubMed Web of Science ®Google Scholar
• Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 2020;8:43. doi:10.3389/fbioe.2020.00043.
   PubMed Web of Science ®Google Scholar
• Salgado AJBOG, et al. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Therapy. 2010; 5:103–110.
   PubMed Web of Science ®Google Scholar
• Fan X-L, Zhang Y, Li X, Fu Q-L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77(14):2771–2794. doi:10.1007/s00018-020-03454-6.
   PubMed Web of Science ®Google Scholar
• Markov A, Thangavelu L, Aravindhan S, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther. 2021;12(1):192. doi:10.1186/s13287-021-02265-1.
   PubMed Web of Science ®Google Scholar
• Dunavin N, Dias A, Li M, McGuirk J. Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease? Biomedicines. 2017;5(3):39. doi:10.3390/biomedicines5030039.
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79–86. doi:10.1007/DCR.0b013e3181973487.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Zhang L, Li J, Zhu C. Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis. Stem Cell Res Ther. 2018;9(1):59. doi:10.1186/s13287-018-0814-4.
   PubMedGoogle Scholar
• Wang Y-H, Wu D-B, Chen B, Chen E-Q, Tang H. Progress in mesenchymal stem cell–based therapy for acute liver failure. Stem Cell Res Ther. 2018;9(1):227. doi:10.1186/s13287-018-0972-4.
   PubMedGoogle Scholar
• Fattizzo B, Giannotta JA, Barcellini W. Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the “seed and soil” crosstalk. Int J Mol Sci. 2020;21(15):5438. doi:10.3390/ijms21155438.
   PubMed Web of Science ®Google Scholar
• Ansboro S, Roelofs AJ, De Bari C. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? Curr Opin Rheumatol. 2017;29(2):201–207. doi:10.1097/BOR.0000000000000370.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Laroni A, Brundin L, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019;20(1):263. doi:10.1186/s13063-019-3346-z.
   PubMedGoogle Scholar
• Volkman R, Offen D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells. 2017;35(8):1867–1880. doi:10.1002/stem.2651.
   PubMed Web of Science ®Google Scholar
• Lo Furno D, Mannino G, Giuffrida R. Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. J Cell Physiol. 2018;233(5):3982–3999. doi:10.1002/jcp.26192.
   PubMed Web of Science ®Google Scholar
• Dasari VR, Veeravalli KK, Dinh DH. Mesenchymal stem cells in the treatment of spinal cord injuries: A review. World J Stem Cells. 2014;6(2):120–133. doi:10.4252/wjsc.v6.i2.120.
   PubMedGoogle Scholar
• Xu R, Feng Z, Wang F-S. Mesenchymal stem cell treatment for COVID-19. eBioMedicine. 2022;77:103920. doi:10.1016/j.ebiom.2022.103920.
   PubMed Web of Science ®Google Scholar
• Kelly K, Rasko JEJ. Mesenchymal stromal cells for the treatment of graft versus host disease. Front Immunol. 2021;12:761616. doi:10.3389/fimmu.2021.761616.
   PubMed Web of Science ®Google Scholar
• Liu S, Liu F, Zhou Y, et al. Immunosuppressive property of MSCs mediated by cell surface receptors. Front Immunol. 2020;11:1076. doi:10.3389/fimmu.2020.01076.
   PubMed Web of Science ®Google Scholar
• Matula Z, Németh A, Lőrincz P, et al. The role of extracellular vesicle and tunneling nanotube-mediated intercellular cross-talk between mesenchymal stem cells and human peripheral T cells. Stem Cells Dev. 2016;25(23):1818–1832. doi:10.1089/scd.2016.0086.
   PubMed Web of Science ®Google Scholar
• Li H, Wang C, He T, et al. Mitochondrial transfer from bone marrow mesenchymal stem cells to motor neurons in spinal cord injury rats via gap junction. Theranostics. 2019;9(7):2017–2035. doi:10.7150/thno.29400.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392–402. doi:10.1016/j.stem.2013.09.006.
   PubMed Web of Science ®Google Scholar
• Eljarrah A, Gergues M, Pobiarzyn PW, Sandiford OA, Rameshwar P. Therapeutic potential of mesenchymal stem cells in immune-mediated diseases. Adv Exp Med Biol. 2019;1201:93–108. doi:10.1007/978-3-030-31206-0_5.
   PubMed Web of Science ®Google Scholar
• Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9(416):1–11. doi:10.1126/scitranslmed.aam7828.
   PubMed Web of Science ®Google Scholar
• Cheung TS, Bertolino GM, Giacomini C, et al. Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers. Front Immunol. 2020;11:1338. doi:10.3389/fimmu.2020.01338.
   PubMed Web of Science ®Google Scholar
• Cheung TS, Galleu A, von Bonin M, Bornhäuser M, Dazzi F. Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cell activity. Haematologica. 2019;104(10):e438–e441. doi:10.3324/haematol.2018.214767.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Q, Tam, PK, et al. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci. 2022;23(17):10023. doi:10.3390/ijms231710023.
   PubMed Web of Science ®Google Scholar
• Kyurkchiev D, Bochev I, Ivanova-Todorova E, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells. 2014;6(5):552–570. doi:10.4252/wjsc.v6.i5.552.
   PubMedGoogle Scholar
• Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712. doi:10.1111/cpr.12712.
   PubMed Web of Science ®Google Scholar
• Molnar V, Pavelić E, Vrdoljak K, et al. Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. Genes (Basel). 2022;13(6):949. doi:10.3390/genes13060949.
   PubMed Web of Science ®Google Scholar
• Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–833. doi:10.1016/j.stem.2018.05.004.
   PubMed Web of Science ®Google Scholar
• Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8(8):784. doi:10.3390/cells8080784.
   PubMed Web of Science ®Google Scholar
• Blanc KL, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(7):804–811. doi:10.1016/j.bbmt.2008.03.012.
   PubMed Web of Science ®Google Scholar
• Murata M, Terakura S, Wake A, et al. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplant. 2021;56(10):2355–2366. doi:10.1038/s41409-021-01304-y.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen S, Yang P, Cao H, Li L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182. doi:10.1186/s13287-019-1287-9.
   PubMedGoogle Scholar
• Li T, Luo C, Zhang J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246. doi:10.1186/s13287-021-02304-x.
   PubMed Web of Science ®Google Scholar
• Doglio M, Crossland RE, Alho AC, et al. Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. Front Immunol. 2022;13:1045168. doi:10.3389/fimmu.2022.1045168.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23(9):1087–1098. doi:10.3727/096368912X661319.
   PubMed Web of Science ®Google Scholar
• Boberg E, von Bahr L, Afram G, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Transl Med. 2020;9(10):1190–1202. doi:10.1002/sctm.20-0099.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Hayes J, Daly A, et al. A Phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):835–844. doi:10.1016/j.bbmt.2019.08.029.
   PubMed Web of Science ®Google Scholar
• Fisher SA, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019;1:175–189.
   Web of Science ®Google Scholar
• Nachmias B, Zimran E, Avni B. Mesenchymal stroma/stem cells: haematologists’ friend or foe? Br J Haematol. 2022;199(2):175–189. doi:10.1111/bjh.18292.
   PubMed Web of Science ®Google Scholar
• Zhao K, Lin R, Fan Z, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22. doi:10.1186/s13045-022-01240-4.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen M, Liao J, et al. Induced pluripotent stem cell-derived mesenchymal stem cells hold lower heterogeneity and great promise in biological research and clinical applications. Front Cell Dev Biol. 2021;9:716907. doi:10.3389/fcell.2021.716907.
   PubMed Web of Science ®Google Scholar
• Zeisbrich M, Becker N, Benner A, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52(10):1399–1405. doi:10.1038/bmt.2017.119.
   PubMed Web of Science ®Google Scholar
• Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118(6):1685–1692. doi:10.1182/blood-2011-02-334821.
   PubMed Web of Science ®Google Scholar
• George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44(2):294–304. doi:10.1111/j.1537-2995.2004.00700.x.
   PubMed Web of Science ®Google Scholar
• Wall SA, Zhao Q, Yearsley M, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2(20):2619–2628. doi:10.1182/bloodadvances.2018020321.
   PubMed Web of Science ®Google Scholar
• Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant. 2021;56(8):1805–1817. doi:10.1038/s41409-021-01283-0.
   PubMed Web of Science ®Google Scholar
• Li Y, Hao J, Hu Z, et al. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 2022;13(1):93. doi:10.1186/s13287-022-02751-0.
   PubMed Web of Science ®Google Scholar
• Jurado M, De La Mata C, Ruiz-García A, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. Cytotherapy. 2017;19(8):927–936. doi:10.1016/j.jcyt.2017.05.002.
   PubMed Web of Science ®Google Scholar
• Bloor AJC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med. 2020;26(11):1720–1725. doi:10.1038/s41591-020-1050-x.
   PubMed Web of Science ®Google Scholar
• Galderisi U, Peluso G, Di Bernardo G. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Rev Rep. 2022;18(1):23–36. doi:10.1007/s12015-021-10231-w.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Abdel-Azim H, Carpenter P, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):845–854. doi:10.1016/j.bbmt.2020.01.018.
   PubMed Web of Science ®Google Scholar
• Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20(3):375–381. doi:10.1016/j.bbmt.2013.11.033.
   PubMed Web of Science ®Google Scholar
• Te Boome LCJ, Mansilla C, van der Wagen LE, et al. Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia. 2015;29(9):1839–1846. doi:10.1038/leu.2015.89.
   PubMed Web of Science ®Google Scholar
• Pérez-Simon JA, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011;96:1072–1076.
   PubMed Web of Science ®Google Scholar
• Servais S, Baron F, Lechanteur C, et al. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. Oncotarget. 2018;9(29):20590–20604. doi:10.18632/oncotarget.25020.
   PubMedGoogle Scholar
• Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant. 2010;16(2):S169–S170. doi:10.1016/j.bbmt.2009.12.057.
   Web of Science ®Google Scholar
• Soder RP, Dawn B, Weiss ML, et al. A phase I study to evaluate two doses of Wharton’s jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease. Stem Cell Rev Rep. 2020;16(5):979–991. doi:10.1007/s12015-020-10015-8.
   PubMed Web of Science ®Google Scholar
• Yi HG, Yahng S-A, Kim I, et al. Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean J Physiol Pharmacol. 2016;20(1):63–67. doi:10.4196/kjpp.2016.20.1.63.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014;20(2):229–235. doi:10.1016/j.bbmt.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Ringden O, Baygan A, Remberger M, et al. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl Med. 2018;7(4):325–331. doi:10.1002/sctm.17-0167.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Remberger M, Gustafsson B, et al. Long-term follow-up of a pilot study using placenta-derived decidua stromal cells for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(10):1965–1969. doi:10.1016/j.bbmt.2019.05.034.
   PubMed Web of Science ®Google Scholar
• Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98(2):206–213. doi:10.1007/s12185-013-1399-4.
   PubMed Web of Science ®Google Scholar
• Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103(2):243–250. doi:10.1007/s12185-015-1915-9.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012;95(2):182–188. doi:10.1007/s12185-011-0989-2.
   PubMed Web of Science ®Google Scholar
• Shen M-Z, Liu X-X, Qiu Z-Y, et al. Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Ther Adv Hematol. 2022;13:20406207211072838. doi:10.1177/20406207211072838.
   Web of Science ®Google Scholar
• Espagnolle N, Balguerie A, Arnaud E, Sensebé L, Varin A. CD54-mediated interaction with pro-inflammatory macrophages increases the immunosuppressive function of human mesenchymal stromal cells. Stem Cell Rep. 2017;8(4):961–976. doi:10.1016/j.stemcr.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Najar M, Krayem M, Merimi M, et al. Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflamm Res. 2018;67(6):467–477. doi:10.1007/s00011-018-1131-1.
   PubMed Web of Science ®Google Scholar
• Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005;33(8):928–934. doi:10.1016/j.exphem.2005.05.002.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14–20. doi:10.1038/mt.2011.211.
   PubMed Web of Science ®Google Scholar
• Kale VP. Application of ‘primed’ mesenchymal stromal cells in hematopoietic stem cell transplantation: current status and future prospects. Stem Cells Dev. 2019;28(22):1473–1479. doi:10.1089/scd.2019.0149.
   PubMed Web of Science ®Google Scholar
• Kim DS, Jang IK, Lee MW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine. 2018;28:261–273. doi:10.1016/j.ebiom.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24(2):386–398. doi:10.1634/stemcells.2005-0008.
   PubMed Web of Science ®Google Scholar
• English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110(2):91–100. doi:10.1016/j.imlet.2007.04.001.
   PubMed Web of Science ®Google Scholar
• Sheng H, Wang Y, Jin Y, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18(8):846–857. doi:10.1038/cr.2008.80.
   PubMed Web of Science ®Google Scholar
• Sarsenova M, Kim Y, Raziyeva K, et al. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells. Front Immunol. 2022;13:1010399. doi:10.3389/fimmu.2022.1010399.
   PubMed Web of Science ®Google Scholar
• Zimmermann JA, Hettiaratchi MH, McDevitt TC. Enhanced immunosuppression of T cells by sustained presentation of bioactive interferon‐γ within three‐dimensional mesenchymal stem cell constructs. Stem Cells Transl Med. 2017;6(1):223–237. doi:10.5966/sctm.2016-0044.
   PubMedGoogle Scholar
• Vigo T, Procaccini C, Ferrara G, et al. IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. J Allergy Clin Immunol. 2017;139(5):1667–1676. doi:10.1016/j.jaci.2016.09.004.
   PubMed Web of Science ®Google Scholar
• de Witte SFH, Franquesa M, Baan CC, Hoogduijn MJ. Toward development of iMesenchymal stem cells for immunomodulatory therapy. Front Immunol. 2015;6:648. doi:10.3389/fimmu.2015.00648.
   PubMed Web of Science ®Google Scholar
• Noronha NdC, Mizukami A, Caliári-Oliveira C, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131. doi:10.1186/s13287-019-1224-y.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang Q, Wang Z, et al. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton’s jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother. 2016;12(1):85–96. doi:10.1080/21645515.2015.1030549.
   PubMed Web of Science ®Google Scholar
• Kanai R, Nakashima A, Doi S, et al. Interferon-γ enhances the therapeutic effect of mesenchymal stem cells on experimental renal fibrosis. Sci Rep. 2021;11(1):850. doi:10.1038/s41598-020-79664-6.
   PubMed Web of Science ®Google Scholar
• Li M, Jiang Y, Hou Q, et al. Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects. Stem Cell Res Ther. 2022;13(1):146. doi:10.1186/s13287-022-02822-2.
   PubMed Web of Science ®Google Scholar
• Croitoru-Lamoury J, Lamoury FMJ, Caristo M, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). Plos One. 2011;6(2):e14698. doi:10.1371/journal.pone.0014698.
   PubMed Web of Science ®Google Scholar
• Noone C, Kihm A, English K, O’Dea S, Mahon BP. IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 2013;22(22):3003–3014. doi:10.1089/scd.2013.0028.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149(2):353–363. doi:10.1111/j.1365-2249.2007.03422.x.
   PubMed Web of Science ®Google Scholar
• Potapova IA, Gaudette GR, Brink PR, et al. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells. 2007;25(7):1761–1768. doi:10.1634/stemcells.2007-0022.
   PubMed Web of Science ®Google Scholar
• Bhang SH, Lee S, Shin J-Y, Lee T-J, Kim B-S. Transplantation of cord blood mesenchymal stem cells as spheroids enhances vascularization. Tissue Eng Part A. 2012;18(19-20):2138–2147. doi:10.1089/ten.TEA.2011.0640.
   PubMed Web of Science ®Google Scholar
• Kouroupis D, Correa D. Increased mesenchymal stem cell functionalization in three-dimensional manufacturing settings for enhanced therapeutic applications. Front Bioeng Biotechnol. 2021;9:621748. doi:10.3389/fbioe.2021.621748.
   PubMed Web of Science ®Google Scholar
• Li, Jianjun, Liu, Yufan, Zhang, Yijie, et al. Biophysical and biochemical cues of biomaterials guide mesenchymal stem cell behaviors. Front Cell Dev Biol. 2021;9:640388. doi:10.3389/fcell.2021.640388.
   PubMed Web of Science ®Google Scholar
• Liu L, He YR, Liu SJ, et al. Enhanced effect of IL-1β-activated adipose-derived MSCs (ADMSCs) on repair of intestinal ischemia-reperfusion injury via COX-2-PGE2 signaling. Stem Cells Int. 2020;2020:e2803747. 2020). doi:10.1155/2020/2803747.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhu X, Cao X, et al. IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate chronic prostatitis/chronic pelvic pain syndrome through systemic immunity. Stem Cell Res Ther. 2021;12(1):514. doi:10.1186/s13287-021-02579-0.
   PubMed Web of Science ®Google Scholar
• Yao M, Cui B, Zhang W, et al. Exosomal miR-21 secreted by IL-1β-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis. Life Sci. 2021;264:118658. doi:10.1016/j.lfs.2020.118658.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906. doi:10.1016/j.immuni.2019.03.021.
   PubMed Web of Science ®Google Scholar
• Sivanathan KN, Rojas-Canales D, Grey ST, Gronthos S, Coates PT. Transcriptome profiling of IL-17A preactivated mesenchymal stem cells: a comparative study to unmodified and IFN-γ modified mesenchymal stem cells. Stem Cells Int. 2017;2017:e1025820. doi:10.1155/2017/1025820.
   PubMed Web of Science ®Google Scholar
• Du-Rocher B, Binato R, de-Freitas-Junior JCM, et al. IL-17 triggers invasive and migratory properties in human MSCs, while IFNy favors their immunosuppressive capabilities: implications for the “licensing” process. Stem Cell Rev Rep. 2020;16(6):1266–1279. doi:10.1007/s12015-020-10051-4.
   PubMed Web of Science ®Google Scholar
• Sivanathan KN, Rojas-Canales DM, Hope CM, et al. Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function. Stem Cells. 2015;33(9):2850–2863. doi:10.1002/stem.2075.
   PubMed Web of Science ®Google Scholar
• Cheng W, et al. Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype. Am J Transl Res. 2017;9:4149–4160.
   PubMed Web of Science ®Google Scholar
• Kook YJ, Lee DH, Song JE, et al. Osteogenesis evaluation of duck’s feet-derived collagen/hydroxyapatite sponges immersed in dexamethasone. Biomater Res. 2017;21(1):2. doi:10.1186/s40824-017-0088-4.
   PubMedGoogle Scholar
• Linares GR, Chiu C-T, Scheuing L, et al. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington’s disease. Exp Neurol. 2016;281:81–92. doi:10.1016/j.expneurol.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Wisel S, Khan M, Kuppusamy ML, et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther. 2009;329(2):543–550. doi:10.1124/jpet.109.150839.
   PubMed Web of Science ®Google Scholar
• Hackel A, Aksamit A, Bruderek K, Lang S, Brandau S. TNF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment. Eur J Immunol. 2021;51(2):319–330. doi:10.1002/eji.201948336.
   PubMed Web of Science ®Google Scholar
• Philipp D, Suhr L, Wahlers T, Choi Y-H, Paunel-Görgülü A. Preconditioning of bone marrow-derived mesenchymal stem cells highly strengthens their potential to promote IL-6-dependent M2b polarization. Stem Cell Res Ther. 2018;9(1):286. doi:10.1186/s13287-018-1039-2.
   PubMed Web of Science ®Google Scholar
• Zhao L, Hu C, Zhang P, Jiang H, Chen J. Novel preconditioning strategies for enhancing the migratory ability of mesenchymal stem cells in acute kidney injury. Stem Cell Res Ther. 2018;9(1):225. doi:10.1186/s13287-018-0973-3.
   PubMedGoogle Scholar
• Gabrielyan A, Neumann E, Gelinsky M, Rösen-Wolff A. Metabolically conditioned media derived from bone marrow stromal cells or human skin fibroblasts act as effective chemoattractants for mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):212. doi:10.1186/s13287-017-0664-5.
   PubMedGoogle Scholar
• Kim Y, Jin HJ, Heo J, et al. Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. Leukemia. 2018;32(12):2672–2684. doi:10.1038/s41375-018-0151-8.
   PubMed Web of Science ®Google Scholar
• Samal JRK, Rangasami VK, Samanta S, Varghese OP, Oommen OP. Discrepancies on the role of oxygen gradient and culture condition on mesenchymal stem cell fate. Adv Healthc Mater. 2021;10(6):e2002058. doi:10.1002/adhm.202002058.
   PubMed Web of Science ®Google Scholar
• Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. Plos One. 2010;5(4):e10088. doi:10.1371/journal.pone.0010088.
   PubMed Web of Science ®Google Scholar
• Gordon S, Mantovani A. Diversity and plasticity of mononuclear phagocytes. Eur J Immunol. 2011;41(9):2470–2472. doi:10.1002/eji.201141988.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Guo J, Mao R, et al. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. Mucosal Immunol. 2017;10(3):727–742. doi:10.1038/mi.2016.78.
   PubMed Web of Science ®Google Scholar
• He X, Wang H, Jin T, et al. TLR4 activation promotes bone marrow MSC proliferation and osteogenic differentiation via Wnt3a and Wnt5a signaling. Plos One. 2016;11(3):e0149876. doi:10.1371/journal.pone.0149876.
   PubMed Web of Science ®Google Scholar
• Rashedi I, Gómez‐Aristizábal A, Wang X-H, Viswanathan S, Keating A. TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via Notch signaling. Stem Cells. 2017;35(1):265–275. doi:10.1002/stem.2485.
   PubMed Web of Science ®Google Scholar
• Linard C, Strup-Perrot C, Lacave-Lapalun J-V, Benderitter M. Flagellin preconditioning enhances the efficacy of mesenchymal stem cells in an irradiation-induced proctitis model. J Leukoc Biol. 2016;100(3):569–580. doi:10.1189/jlb.3A0915-393R.
   PubMed Web of Science ®Google Scholar
• Vijayan A, Rumbo M, Carnoy C, Sirard J-C. Compartmentalized antimicrobial defenses in response to flagellin. Trends Microbiol. 2018;26(5):423–435. doi:10.1016/j.tim.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Sangiorgi BB, Leão V, Lilian dos Santos Schiavinato J, et al. TLR9 priming promotes proliferation of mesenchymal stem cells and restores the immunosuppressive activity impaired by TLR4 priming: potential involvement of non-canonical NF-kb signaling. Blood. 2013;122(21):2458–2458. doi:10.1182/blood.V122.21.2458.2458.
   Web of Science ®Google Scholar
• Alvites R, Branquinho M, Sousa AC, et al. Mesenchymal stem/stromal cells and their paracrine activity—immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics. 2022;14(2):381. doi:10.3390/pharmaceutics14020381.
   PubMed Web of Science ®Google Scholar
• Lee B-C, Kang K-S. Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application. Stem Cell Res Ther. 2020;11(1):397. doi:10.1186/s13287-020-01920-3.
   PubMed Web of Science ®Google Scholar
• Kang HK, Sarsenova M, Kim D-H, et al. Establishing a 3D in vitro hepatic model mimicking physiologically relevant to in vivo state. Cells. 2021;10(5):1268. doi:10.3390/cells10051268.
   PubMed Web of Science ®Google Scholar
• Sart S, Ma T, Li Y. Preconditioning stem cells for in vivo delivery. Biores Open Access. 2014;3(4):137–149. doi:10.1089/biores.2014.0012.
   PubMedGoogle Scholar
• Petrenko Y, Syková E, Kubinová Š. The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids. Stem Cell Res Ther. 2017;8(1):94. doi:10.1186/s13287-017-0558-6.
   PubMedGoogle Scholar
• Trivanovic D, Volkmann N, Stoeckl M, et al. Enhancement of immunosuppressive activity of mesenchymal stromal cells by platelet-derived factors is accompanied by apoptotic priming. Stem Cell Rev Rep. 2023;19(3):713–733. doi:10.1007/s12015-022-10471-4.
   PubMed Web of Science ®Google Scholar
• Vial S, Reis RL, Oliveira JM. Recent advances using gold nanoparticles as a promising multimodal tool for tissue engineering and regenerative medicine. Curr Opin Solid State Mater Sci. 2017;21(2):92–112. doi:10.1016/j.cossms.2016.03.006.
   Web of Science ®Google Scholar
• Hung H-S, Kung M-L, Chen F-C, et al. Nanogold-carried graphene oxide: anti-inflammation and increased differentiation capacity of mesenchymal stem cells. Nanomaterials (Basel). 2021;11(8):2046. doi:10.3390/nano11082046.
   PubMedGoogle Scholar
• Fathi-Achachelouei M, Knopf-Marques H, Ribeiro da Silva CE, et al. Use of nanoparticles in tissue engineering and regenerative medicine. Front Bioeng Biotechnol. 2019;7:113. doi:10.3389/fbioe.2019.00113.
   PubMed Web of Science ®Google Scholar
• Geetha Bai R, Muthoosamy K, Manickam S, Hilal-Alnaqbi A. Graphene-based 3D scaffolds in tissue engineering: fabrication, applications, and future scope in liver tissue engineering. Int J Nanomedicine. 2019;14:5753–5783. doi:10.2147/IJN.S192779.
   PubMed Web of Science ®Google Scholar
• Hnatiuk AP, Ong S-G, Olea FD, et al. Allogeneic mesenchymal stromal cells overexpressing mutant human hypoxia‐inducible factor 1‐α (HIF1‐α) in an ovine model of acute myocardial infarction. J Am Heart Assoc. 2016;5(7):e003714. doi:10.1161/JAHA.116.003714.
   PubMed Web of Science ®Google Scholar
• Yang J-X, Zhang N, Wang H-W, et al. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats *. J Biol Chem. 2015;290(4):1994–2006. doi:10.1074/jbc.M114.605063.
   PubMed Web of Science ®Google Scholar
• Nie W-B, Zhang D, Wang L-S. Growth factor gene-modified mesenchymal stem cells in tissue regeneration. Drug Des Devel Ther. 2020;14:1241–1256. doi:10.2147/DDDT.S243944.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim H-S, Roh K-H, et al. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells. Sci Rep. 2015;5(1):8020. doi:10.1038/srep08020.
   PubMedGoogle Scholar
• Bergmann CA, Beltran S, Vega-Letter AM, et al. The autophagy protein pacer positively regulates the therapeutic potential of mesenchymal stem cells in a mouse model of DSS-induced colitis. Cells. 2022;11(9):1503. doi:10.3390/cells11091503.
   PubMed Web of Science ®Google Scholar
• Cen S, Wang P, Xie Z, et al. Autophagy enhances mesenchymal stem cell-mediated CD4+ T cell migration and differentiation through CXCL8 and TGF-β1. Stem Cell Res Ther. 2019;10(1):265. doi:10.1186/s13287-019-1380-0.
   PubMed Web of Science ®Google Scholar
• Tian J, Kou X, Wang R, et al. Autophagy controls mesenchymal stem cell therapy in psychological stress colitis mice. Autophagy. 2021;17(9):2586–2603. doi:10.1080/15548627.2020.1821547.
   PubMed Web of Science ®Google Scholar
• An J-H, Li Q, Ryu M-O, et al. TSG-6 in extracellular vesicles from canine mesenchymal stem/stromal is a major factor in relieving DSS-induced colitis. Plos One. 2020;15(2):e0220756. doi:10.1371/journal.pone.0220756.
   PubMed Web of Science ®Google Scholar
• Negi N, Griffin MD. Effects of mesenchymal stromal cells on regulatory T cells: current understanding and clinical relevance. Stem Cells. 2020;38(5):596–605. doi:10.1002/stem.3151.
   PubMed Web of Science ®Google Scholar
• Silva-Carvalho AÉ, Rodrigues LP, Schiavinato JL, et al. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):156. doi:10.1186/s13287-020-01659-x.
   PubMed Web of Science ®Google Scholar
• Oses C, Olivares B, Ezquer M, et al. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: potential application in the treatment of diabetic neuropathy. Plos One. 2017;12(5):e0178011. doi:10.1371/journal.pone.0178011.
   PubMed Web of Science ®Google Scholar
• Smadja DM, Levy M, Huang L, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015;114(4):735–747. doi:10.1160/TH14-11-0907.
   PubMed Web of Science ®Google Scholar
• Pourjafar M, Saidijam M, Mansouri K, et al. All-trans retinoic acid preconditioning enhances proliferation, angiogenesis and migration of mesenchymal stem cell in vitro and enhances wound repair in vivo. Cell Prolif. 2017;50(1):e12315. doi:10.1111/cpr.12315.
   PubMed Web of Science ®Google Scholar
• Zhang R, Yin L, Zhang B, et al. Resveratrol improves human umbilical cord-derived mesenchymal stem cells repair for cisplatin-induced acute kidney injury. Cell Death Dis. 2018;9(10):965. doi:10.1038/s41419-018-0959-1.
   PubMed Web of Science ®Google Scholar
• Yang Z, Concannon J, Ng KS, et al. Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation. Sci Rep. 2016;6(1):30263. doi:10.1038/srep30263.
   PubMedGoogle Scholar
• Kiselevskii MV, Vlasenko RY, Stepanyan NG, et al. Secretome of mesenchymal bone marrow stem cells: is it immunosuppressive or proinflammatory? Bull Exp Biol Med. 2021;172(2):250–253. doi:10.1007/s10517-021-05371-5.
   PubMed Web of Science ®Google Scholar
• Munoz-Perez E, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Mesenchymal stromal cell secretome for the treatment of immune-mediated inflammatory diseases: latest trends in isolation, content optimization and delivery avenues. Pharmaceutics. 2021;13(11):1802. doi:10.3390/pharmaceutics13111802.
   PubMed Web of Science ®Google Scholar
• Lai P, Chen X, Guo L, et al. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol. 2018;11(1):135. doi:10.1186/s13045-018-0680-7.
   PubMedGoogle Scholar
• Dal Collo G, Adamo A, Gatti A, et al. Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease. Stem Cells. 2020;38(5):698–711. doi:10.1002/stem.3160.
   PubMed Web of Science ®Google Scholar
• Wang L, Gu Z, Zhao X, et al. Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. Stem Cells Dev. 2016;25(24):1874–1883. doi:10.1089/scd.2016.0107.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yeo RWY, Lai RC, et al. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway. Cytotherapy. 2018;20(5):687–696. doi:10.1016/j.jcyt.2018.02.372.
   PubMed Web of Science ®Google Scholar
• Fujii S, Miura Y, Fujishiro A, et al. Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations. Stem Cells. 2018;36(3):434–445. doi:10.1002/stem.2759.
   PubMed Web of Science ®Google Scholar